Lineage Cell Therapeutics, Inc. BTX Income Statement

Lineage cell therapeutics, inc. (BTX)

Income statement / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Sep'10	Jun'10
REVENUES:
Grant revenue
348	409	350	529	749	587	718	1,941	326	-	1,225	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Royalties from product sales and license fees
166	831	164	140	86	80	85	91	136	-	86	81	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Grant revenue
-	-	-	-	-	-	-	-	-	-	-	-	11	315	1,109	760	1,487	900	1,466	1,437	699	1,433	648	640	575	628	160	693	90	707	441	672	400	1,162	746	442	415	418	395
License fees
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	300	294	-	382	362	349	350	337	175	36	62	54	41	104	73	58
Royalties from product sales and license fees
-	-	-	-	-	-	-	-	-	-	-	-	110	81	177	86	200	89	357	117	156	76	148	76	97	75	80	103	107	133	133	126	147	187	176	177	215	215	215
Subscription and advertisement revenues
-	-	-	-	-	0	119	333	239	455	376	300	264	272	69	288	343	338	343	357	319	-	285	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Sale of research products and services
-	1	53	110	93	-	60	182	-	-	1	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total revenues
514	1,241	567	779	928	758	982	2,547	701	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Sale of research products and services
-	-	-	-	-	-	-	-	-	-	-	-	5	417	144	132	43	130	140	98	90	76	110	91	98	61	90	57	66	34	90	59	67	254	184	119	88	108	11
Total revenues
-	-	-	-	-	-	-	-	-	-	-	-	390	1,085	1,499	1,266	2,073	1,457	2,306	2,009	1,264	1,879	1,191	1,107	1,066	1,889	714	1,216	614	1,225	1,003	1,033	652	-	-	-	824	815	680
Total revenues
-	-	-	-	-	-	-	-	-	-	1,688	381	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,161	780	-	-	-
Cost of sales
94	123	114	107	68	52	35	106	109	54	52	5	57	-20	58	95	225	151	432	260	264	222	231	252	131	222	206	180	182	160	169	83	20	-	18	24	-	-	-
Gross profit
420	1,118	453	672	860	706	947	2,441	592	945	1,636	376	333	1,105	1,441	1,171	1,848	1,306	1,874	1,749	1,000	1,657	960	855	934	1,666	507	1,035	431	1,065	833	949	631	-	1,143	755	-	-	-
OPERATING EXPENSES:
Research and development
3,339	3,486	4,266	5,235	4,961	3,780	4,882	6,358	5,935	4,697	6,562	6,271	6,494	7,012	6,422	8,938	13,734	12,789	11,433	9,059	9,323	11,210	8,836	9,081	8,405	9,241	6,441	5,530	5,395	4,777	4,545	4,615	4,178	3,929	3,488	3,333	2,948	-1,808	-1,429
Acquired in-process research and development
-	-	-	-	-	-	-	-	800	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and administrative
4,519	4,504	4,609	6,258	8,660	7,033	6,422	5,227	6,044	5,811	4,587	4,423	5,101	5,344	4,574	6,636	11,872	10,224	7,545	6,186	5,179	4,790	4,262	4,836	3,667	4,253	4,267	3,621	3,416	3,347	2,234	2,413	2,368	3,149	1,887	2,402	1,901	-1,464	-1,566
Total operating expenses
7,858	30,976	8,875	-11,493	13,621	59,541	11,304	-11,585	-12,779	33,698	11,149	10,694	-11,595	12,356	10,996	15,574	25,606	23,013	18,978	15,245	14,502	16,001	13,098	13,917	12,072	30,954	10,709	9,151	8,811	8,124	6,780	7,029	6,547	7,078	5,375	5,736	4,850	-3,272	2,995
Gain on sale of assets
-	-	-	-	-	-	-	-	-	-	0	1,754	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss from operations
-7,438	-6,872	-8,422	-10,821	-12,761	-10,107	-10,357	-9,144	-12,187	-9,563	-9,513	-8,564	-11,262	-11,251	-9,555	-14,403	-23,758	-21,707	-17,104	-13,496	-13,502	-14,344	-12,138	-13,062	-11,137	-29,287	-10,201	-8,116	-8,379	-7,059	-5,946	-6,079	-5,915	-5,447	-4,232	-4,980	-4,025	-2,457	-2,315
OTHER INCOME/(EXPENSES):
Interest income, net
405	-	-	-	442	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest income (expense), net
-	-	399	437	-	433	174	52	52	37	-10	-413	-306	-372	-167	-76	-132	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain on sale of marketable equity securities
1,258	-	2,055	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain on sale of AgeX shares and deconsolidation of AgeX
-	-	-	-	-	-	78,511	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain on sale of equity method investment in Ascendance
-	-	-	-	-	-	-	-	3,215	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest income/(expense), net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-12	4	-25	-	-7	-10	-8	-2	0	0	0	2	5	3	8	8	2	5	13	-0	-0
BioTimes share of losses and impairment in equity method investment in Ascendance
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-235	-35	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain on sale of shares and deconsolidation
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss on equity method investment in Asterias at fair value
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(Loss) gain on equity method investment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Unrealized (loss) gain on marketable equity securities
-1,338	236	-4,458	-607	1,931	523	23	397	215	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Unrealized gain on warrant liability
35	261	79	234	37	-	21	460	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss on extinguishment of related party convertible debt
-	-	-	-	-	-	-	-	-	-	-2,799	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other (expense) income, net
-1,350	262	582	882	806	-677	-7	-839	-176	248	-143	617	727	-595	-173	237	128	428	-573	225	-240	-	-119	-	-	-	-	-	-	-	-	-	-	-	-4	-19	-	-	-
(Loss)/gain on sale or write off of fixed assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5	0	-1	-	-1	-3	-	-	-	0	-	0	-
Modification cost of warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-2,142	-
Gain/(loss) on sale of fixed assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-6	-	-	-	-
Other income, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	165	69	-	-60	-80	-28	-94	18	85	-327	176	-0	-24	68	-202	-38
Total other (expense) income, net
-990	1,532	-9,084	-20,479	47,673	-35,223	76,901	4,498	-51,511	-67,281	28,271	-7,540	62,163	3,379	38,820	35,628	-239	3,780	-585	229	-265	-562	-126	155	60	-41	-54	-79	-28	-94	22	85	-318	-	-	-	81	-2,343	-38
(LOSS)/INCOME BEFORE INCOME TAXES
-8,428	-5,340	-17,506	-31,300	34,912	-45,330	66,544	-4,646	-63,698	-76,844	18,758	-16,104	50,901	-7,872	29,265	21,225	-23,997	-17,927	-17,689	-13,267	-13,767	-14,906	-12,264	-12,907	-11,077	-29,330	-10,256	-8,195	-8,408	-	-	-	-	-	-	-	-	-	-
Deferred income tax benefit
-	-	-991	-1,248	-	-	-	-	-	-	4,772	-3,877	3,877	0	0	0	0	-1,120	-948	-1,271	-1,177	-2,200	-2,313	-1,513	-1,349	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred income tax benefit
-	-	-	-	4,384	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-
NET (LOSS)/INCOME
-8,428	-4,556	-16,515	-30,052	39,296	-44,984	66,544	-4,646	-63,698	-72,072	13,986	-12,227	47,024	-7,872	29,265	21,225	-23,997	-16,807	-16,741	-11,996	-12,590	-12,705	-9,951	-11,394	-9,728	-26,049	-10,256	-8,195	-8,408	-7,153	-5,923	-5,994	-6,234	-5,262	-4,236	-5,000	-3,944	-4,801	-2,353
Net loss attributable to noncontrolling interest
-29	-74	-10	-20	-14	-32	-181	-431	-150	-138	-335	-576	-2,264	-2,808	-1,934	-3,324	-6,885	-8,146	-3,115	-2,305	2,423	-5,439	-1,683	-1,874	1,629	-6,437	-1,253	-645	-689	-1,116	-965	-537	-1,260	-124	-498	-722	-582	130	-94
NET (LOSS)/INCOME ATTRIBUTABLE TO LINEAGE CELL THERAPEUTICS, INC.
-8,399	-4,482	-16,505	-30,032	39,310	-44,952	66,725	-4,215	-63,548	-71,934	14,321	-11,651	49,288	-5,064	31,199	24,549	-17,112	-13,507	-13,626	-9,691	-10,167	-	-8,268	-9,520	-	-19,610	-9,003	-7,549	-7,719	-6,037	-4,958	-5,457	-4,973	-5,137	-3,737	-4,277	-3,362	-4,671	-2,259
NET (LOSS)/INCOME PER COMMON SHARE:
Dividends on preferred shares
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	363	52	-	-	34	34	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-
NET INCOME (LOSS) ATTRIBUTABLE TO BIOTIME, INC. COMMON SHAREHOLDERS
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-13,989	-9,743	-	-10,543	-8,302	-9,554	-8,099	-	-9,003	-7,549	-	-	-	-	-	-	-	-	-	-	-
Unrealized loss on available-for-sale assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-
Foreign currency translation (loss)/gain
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7	28	148	-	-15	-182	124	-	696	-928	-	-	-
Foreign currency translation gain/(loss)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-670	3	-5
TOTAL COMPREHENSIVE NET LOSS
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-8,996	-7,520	-7,570	-	-4,973	-5,640	-4,849	-5,256	-3,040	-5,206	-4,032	-4,667	-2,265
BASIC AND DILUTED
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.13	-	-0.12	-0.16	-0.14	-0.36	-0.16	-0.14	-0.15	-0.13	-0.10	-0.11	-0.10	-0.11	-0.08	-0.09	-0.07	-0.11	-0.06
BASIC
-0.06	-	-0.11	-0.20	0.30	-	0.53	-0.03	-0.50	-	0.12	-0.11	0.46	-0.02	0.30	0.26	-0.19	-	-0.18	-0.12	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
DILUTED
-0.06	-	-0.11	-0.20	0.30	-	0.53	-0.03	-0.50	-	0.12	-0.11	0.46	-0.03	0.30	0.26	-0.19	-	-0.18	-0.12	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING:
BASIC
149,807	-	149,659	149,582	132,865	-	126,878	126,873	126,869	-	115,288	110,874	106	388,977	102	93	90	-	79	78	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
DILUTED
149,807	-	149,659	149,582	132,869	-	126,973	126,873	126,869	-	115,298	110,874	107	397,922	103	95	90	-	79	78	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
BASIC AND DILUTED
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	78,262	-	67,921	61,498	58,257	56,315	55,621	53,791	51,175	47,979	49,291	50,548	49,035	-	48,896	48,835	-	-	-
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING: BASIC AND DILUTED (in shares)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	48,306	42,653	37,562
OncoCyte Corporation [Member]
(Loss) gain on equity method investment
-	-	-	-21,425	-	-	-	6,603	-37,419	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain on equity method investment
-	-	546	-	37,713	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Unrealized (loss) gain on equity method investment
-	-	-8,287	-	-	-	-734	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Asterias Biotherapeutics [Member]
(Loss) gain on equity method investment
-	-	-	-	-	-	-	-2,175	-17,398	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain on equity method investment
-	-	-	-	6,744	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Unrealized (loss) gain on equity method investment
-	-	-	-	-	-	-1,087	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-